An Observational Modified Prescription-event Monitoring Study of Asenapine (Sycrest)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

122 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-31

Study Completion Date

2018-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This post-marketing Modified Prescription-Event Monitoring (M-PEM) safety study of asenapine (SYCREST®) is to be carried out by the Drug Safety Research Unit (DSRU) as part of the Risk Management Plan required by the Committee for Medicinal Products for Human Use (CHMP) to further investigate the safety profile of asenapine in clinical practice. The aim of this study is to proactively capture safety and drug utilisation data in the post-marketing phase of license approval of asenapine as prescribed to patients by general practitioners (GPs) in England. This data is obtained through the completion of questionnaires by GPs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)

NCT01495741

Bipolar Disorder Schizophrenia

COMPLETED

An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

NCT01498770

Bipolar Disorder

COMPLETED

Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)

NCT00764478

Bipolar 1 Disorder

COMPLETED PHASE3

40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)

NCT00159783

Bipolar Disorder

COMPLETED PHASE3

The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours

NCT01377896

Schizophrenia Bipolar Disorders Major Depressive Disorders

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar I Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Asenapine

Patients prescribed asenapine for any indication by a National Health Service (NHS) general practitioner (GP) in England.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients prescribed asenapine for any indication by NHS GPs in England.
* Patients for whom a study questionnaire containing useful information has been returned, will be included in the study cohort regardless of the dose or frequency of administration of asenapine, and irrespective of whether any medicines are concurrently administered.

Exclusion Criteria

* patient no longer registered with the practice
* patient for whom no information is provided on study questionnaire
* patients for whom information provided on study questionnaire relates to another antipsychotic drug
* patients for whom the index date is an improbable date (i.e. before market launch date)
* patients for whom the GP reports that the patient did not take or was never prescribed asenapine

Eligible Sex

ALL

Accepts Healthy Volunteers

No